Karthik Kumar Joins InClinica as Business Development Manager

Press Releases

Karthik Kumar Joins InClinica as Business Development Manager

 

PHILADELPHIA (April 18, 2018)InClinica, a global clinical CRO, announced today that Karthikeyan (Karthik) Kumar has been appointed Business Development Manager in the company’s office in Kuala Lumpur, Malaysia.

In his new role, Kumar will be responsible for supporting clinical research organization sales and business development activities, generating leads, and providing customer relationship management and clinical operations management support.

“Karthik will make an excellent addition to the InClinica team in Malaysia,” said James Nolan, CEO at InClinica. “His business experience coupled with strong clinical operations knowledge will contribute to the expansion of our business and help build the company’s presence in Asia’s booming clinical arena.”

Kumar has more than 12 years of experience in pharmaceuticals and clinical research. Prior to joining InClinica, Kumar served as Assistant Manager at Siro Clinipharm and was responsible for managing all operations in Malaysia and Singapore. He spent ten years with the company, and his work has ranged from Phase I to IV mult-centric studies, pilot and in-house studies. Kumar has also served in roles at Natural Remedies and ClinWorld.

Kumar received his bachelor’s and master’s degrees in biochemistry from Bharathidasan University, and his MBA from National Institute of Business Management. He is expected to earn a doctorate in clinical research from University of Central Nicaragua in May 2018.

About InClinica

InClinica is a global clinical contract research organization founded in 2016 after the acquisition of an existing global CRO. With a senior management team that brings more than 100 combined years of experience, InClinica works across all phases of the clinical research process and has a particular strength in first in man and phase 2 studies. InClinica is headquartered in Philadelphia with other locations in the U.K., Israel, and Malaysia/Singapore.